Glimp M 2 SR Tablet is a combination oral antihyperglycemic medication containing Glimepiride 2 mg and Metformin 500 mg, formulated to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glucose uptake and utilization. The sustained-release (SR) formulation of Glimp M 2 SR allows for gradual drug release, promoting steady plasma concentrations and enhancing patient compliance through once-daily dosing. This combination is indicated for adults inadequately controlled on diet and exercise alone or those not responding sufficiently to monotherapy with either agent. It is essential to monitor renal function prior to and during treatment, as Metformin is contraindicated in patients with significant renal impairment due to the risk of lactic acidosis. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while hypoglycemia is a potential risk associated with Glimepiride. Glimp M 2 SR should be used under medical supervision with regular monitoring of blood glucose levels to optimize therapeutic outcomes and minimize adverse effects.